Prothena Corporation (PRTA) SEC Filings: History & Chart

Prothena Corporation plc(PRTA)

Biotechnology · Dublin, DU

$8.08-0.19 (-2.30%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Dublin, DU

67 employees

www.prothena.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gene G. Kinney

View full financials

Form	Filing Date	Accepted	Document
8-K	Oct 2, 2026	Oct 2, 2026	View filing
4	Sep 30, 2026	Sep 30, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 21, 2026	Sep 21, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 21, 2026	Aug 21, 2026	View filing
SC 13G/A	Aug 19, 2026	Aug 19, 2026	View filing
3	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
4	Aug 11, 2026	Aug 11, 2026	View filing
3	Aug 11, 2026	Aug 11, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G/A	Aug 6, 2026	Aug 6, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
4	Jul 30, 2026	Jul 30, 2026	View filing
SC 13G/A	Jul 29, 2026	Jul 29, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
3	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing

SEC Filings

Recent Filings